EP3766581A1 - Mikrofluidvorrichtung, die eine reaktionskammer zur verstärkung umfasst - Google Patents
Mikrofluidvorrichtung, die eine reaktionskammer zur verstärkung umfasst Download PDFInfo
- Publication number
- EP3766581A1 EP3766581A1 EP20184842.1A EP20184842A EP3766581A1 EP 3766581 A1 EP3766581 A1 EP 3766581A1 EP 20184842 A EP20184842 A EP 20184842A EP 3766581 A1 EP3766581 A1 EP 3766581A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- chamber
- amplification
- zone
- alcove
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003321 amplification Effects 0.000 title claims abstract description 89
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 89
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 37
- 230000003287 optical effect Effects 0.000 claims abstract description 37
- 238000001514 detection method Methods 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 238000004458 analytical method Methods 0.000 claims abstract description 12
- 239000012472 biological sample Substances 0.000 claims abstract description 12
- 239000000523 sample Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 108020001019 DNA Primers Proteins 0.000 claims description 2
- 239000003155 DNA primer Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 description 24
- 241000894007 species Species 0.000 description 18
- 239000012620 biological material Substances 0.000 description 14
- 238000012546 transfer Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 7
- 239000013615 primer Substances 0.000 description 6
- 235000021183 entrée Nutrition 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 4
- 239000003344 environmental pollutant Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 231100000719 pollutant Toxicity 0.000 description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 4
- 239000004926 polymethyl methacrylate Substances 0.000 description 4
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 2
- 241001639412 Verres Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 241001272720 Medialuna californiensis Species 0.000 description 1
- -1 Polytetrafluoroethylene Polymers 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502707—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the manufacture of the container or its components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L9/00—Supporting devices; Holding devices
- B01L9/52—Supports specially adapted for flat sample carriers, e.g. for plates, slides, chips
- B01L9/527—Supports specially adapted for flat sample carriers, e.g. for plates, slides, chips for microfluidic devices, e.g. used for lab-on-a-chip
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
- B01L2200/027—Fluid interfacing between devices or objects, e.g. connectors, inlet details for microfluidic devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/14—Process control and prevention of errors
- B01L2200/143—Quality control, feedback systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0654—Lenses; Optical fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0848—Specific forms of parts of containers
- B01L2300/0851—Bottom walls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0848—Specific forms of parts of containers
- B01L2300/0858—Side walls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0887—Laminated structure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Definitions
- the present invention relates to a microfluidic system, more particularly to the architecture of a chamber located in a device of the system and intended for carrying out an amplification reaction.
- the qPCR-type reaction consists of an amplification of a targeted DNA or RNA sequence (representative of a particular organism) coupled to an intercalator or to a probe producing a fluorescence detectable by an optical device in the event of amplification of this sequence.
- a targeted DNA or RNA sequence representedative of a particular organism
- an intercalator or to a probe producing a fluorescence detectable by an optical device in the event of amplification of this sequence.
- the invention therefore aims to provide a microfluidic system provided with an integrated solution for monitoring the amplification reaction or for identifying several targets during the same analysis.
- the amplification chamber comprises a first volume having a first section and a second volume having a second section narrowed with respect to said first section so as to form a protrusion, said protrusion forming said alcove.
- said support comprises several superimposed layers and said amplification chamber is produced by at least two of said superimposed layers, called upper layer and lower layer, said alcove is made in one of said two layers only.
- said protrusion forming said alcove is made in the lower stratum.
- the amplification chamber comprises a main cavity produced in the upper stratum and one or more secondary cavities produced in the lower stratum and each forming another alcove of said chamber.
- the internal reaction control compound comprises a known DNA sequence or a set of DNA primers aimed at a predefined DNA target, allowing its amplification according to the amplification method used.
- the first zone of the chamber is transparent in order to allow an optical signal supplied by a source of the detection device to pass and the second zone has at least one opaque part configured so as not to allow said optical signal to pass.
- the microfluidic device of the invention is intended for the analysis of a biological sample.
- This biological sample is for example in the form of a fluid which contains biological species containing a biological material to be studied.
- RNA nucleic acid molecules
- LPS lipopolysaccharides
- LTA lipoteichoic acids
- fluid is understood to mean in particular a liquid, a gas, etc.
- the liquid may have different degrees of viscosity and may for example be in the form of a paste or a gel.
- the biological sample for example in liquid form, comprising the biological species
- the biological sample is injected into a chamber to pass through a filter.
- the liquid part of the sample and any particles / molecules which pass through the filter are collected by a discharge channel and removed from the analysis.
- the biological species are then concentrated in a space of the chamber.
- a wash / rinse solution can be injected to wash the biological species present in the chamber.
- a culture medium is injected to allow the culture of the biological species.
- the growth monitoring step makes it possible, by optical reading, using a sensor C, to monitor cell growth during the culture step.
- the mechanical lysis of the biological species is implemented to crush the biological species present in the sample against a rough bearing surface. Once the mechanical lysis has been carried out, there is a biological material to study, formed for example of DNA molecules and pollutants.
- the separation between the biological material to be studied and the pollutants is carried out by injecting a liquid solution containing amplification reagents, to elute the biological material to be studied. Part of the injected liquid solution thus carries away the biological material to be studied, for example DNA molecules, which passes through the filter.
- the amplification reaction of the biological material makes it possible to detect the presence of a pathogen in the biological material which has been separated.
- the amplification reaction is carried out by adding an amplification mixture and heating a chamber in which the sample is placed.
- the temperature to which the chamber is heated depends on the type of amplification reaction carried out. It could be all types of amplification reaction, for example LAMP ("Loop-Mediated Isothermal Amplification"), PCR ("Polymerase Chain Reaction"), NASBA ("Nucleic Acid Sequence Based Amplification”), RPA (" Recombinase Polymerase Amplification ”) ...
- the heating is carried out at a temperature advantageously between 60 ° C and 65 ° C.
- This reaction makes it possible to amplify the molecules of the biological material to be detected, for example DNA molecules.
- amplification reaction of biological material it is a question of detecting whether a pathogen is present.
- different methods such as for example colorimetry, fluorescence, electrochemistry, pHmetry, measurement of turbidity. Any other method of detection could be considered.
- pH detection electrodes could be integrated into the device.
- FIG 2 A microfluidic device making it possible to carry out the steps described above is shown in figure 2 .
- This device comprises a single rigid support S.
- the figure 3 described below gives an exemplary embodiment of the device.
- This rigid support S integrates a microfluidic network adapted to the implementation of the steps of the analysis method. It will be seen that the microfluidic network can take different architectures depending on the configuration of the analysis process which is implemented.
- the support S advantageously comprises a flat lower wall and an architecture with several superimposed layers along said main axis, stacked on its lower wall.
- the microfluidic network of the device comprises at least two units U1, U2
- the first unit U1 comprises a first chamber 10 formed in said support.
- This chamber 10 has a non-zero volume and is delimited by the walls of the support S.
- the first unit U1 comprises a first channel 11 formed in the support for injecting fluids into the first chamber 10 or for discharging fluids outside this first chamber.
- the first channel 11 has a first end comprising an opening formed for example through an upper wall of the support S and a second end which opens into said first chamber 10.
- the first end of the first channel is for example arranged vertically and its second end opens out. for example horizontally in the first chamber 10.
- the first unit U1 comprises a second channel 12.
- This second channel 12 also comprises a first end which communicates with the outside, forming an opening made for example through an upper wall of the support S and a second end which communicates with the space. formed by the first chamber 10. Via this second channel 12, it is also possible to inject fluids into said first chamber or to evacuate fluids outside of said first chamber. Its first end is for example arranged vertically and its second end horizontally.
- the first chamber 10 is placed between the first channel 11 and the second channel 12.
- the first chamber 10 can be closed by a flexible and stretchable membrane 13.
- an upper wall of the support thus comprises an opening which is covered in a hermetic manner by said membrane 13.
- the membrane 13 is thus anchored in the support by any suitable fixing solution, for example by gluing.
- This membrane 13 will for example be composed of a film, for example of MicroAmp, 3M (registered trademarks) type, of thickness, dimensions and constitution adapted to deform in a hyper-elastic manner, with respect to its points of anchoring, at least to the bottom of the first chamber.
- the membrane 13 is able to deform in a reversible manner between several configurations. It can stretch by hyper-elastic deformation towards the outside of the support S, retract inside the first chamber 10 by compression, or be at rest.
- hyper-elastic material is meant a material capable of presenting a surface capable of passing from a first surface to a second surface, the second surface being equal to at least 5 times the first surface area, for example 10 times or even to 50 times the first area.
- the first unit U1 also comprises a transverse filter 14 arranged in said first chamber 10 and separating said first chamber 10 into two spaces. 100, 101.
- the two spaces are for example superimposed and thus designated the lower space 100 located under the filter 14 and the upper space 101 located above the filter 14.
- This filter 14 is preferably produced in whole or in part in the form of a flexible and thin film, drawn in the space formed by the chamber so as to allow passage from one space to another only through the pores of the filter 14.
- the film has an elastic deformability allowing it to stretch during the exercise of a support force in a substantially vertical direction, this elastic deformability having a level sufficient to reach the bottom of the chamber 10.
- the filter 14 has an average pore diameter of between 0.2 ⁇ m and 50 ⁇ m, for example between 0.2 ⁇ m and 1 ⁇ m for the separation of microorganisms.
- the diameter of the pores is of course adapted to ensure a separation between different biological species present in the sample.
- the filter 14 will for example be composed of a film of thickness, dimensions and constitution adapted to deform to the bottom of the chamber 10 relative to its anchoring points. It may have the same hyper-elasticity characteristics as the membrane.
- the first channel 11 opens into the upper space 101 of the first chamber 10 and the second channel 12 opens into the lower space 100 of the first chamber 10.
- the mouths of the two channels are therefore separated by the filter 14. arranged in the bedroom.
- the first unit U1 can advantageously comprise a rough bearing surface 15 arranged on the bottom of the first chamber 10.
- This rough bearing surface 15 extends over a majority part of the bottom of the first chamber. It includes an average surface roughness parameter between 0.1 ⁇ m and 10 ⁇ m, preferably between 0.2 ⁇ m and 3 ⁇ m.
- This rough bearing surface 15 is intended to allow mechanical lysis of the biological species present in a biological sample placed in the device.
- the mechanical lysis is carried out by grinding said biological species, by abrasion on said rough bearing surface.
- the grinding operation is carried out by a friction movement of the biological species against the rough bearing surface, using a suitable grinding member.
- This member will for example be a spatula or a rod, for example made of plastic or metallic material.
- This member is applied from the outside of the chamber 10 and its end is applied against the outer surface of the membrane 13 so as to stretch the membrane 13 and the filter 14 towards the bottom of the first chamber 10 and thus rub the biological species. present in a sample against the rough bearing surface 15.
- the second unit U2 of the device for its part comprises a second chamber 20 of non-zero volume, delimited by the walls of the support S.
- the second unit U2 also comprises a third channel 21 formed in said support.
- This third channel 21 has a first end comprising an opening formed for example through an upper wall of the support and a second end which opens only into said second chamber 20.
- the first end of this third channel 21 is for example arranged vertically and its second one end opens, for example, horizontally into the second chamber 20.
- the first end of this third channel is for example closed by a hydrophobic membrane 210, that is to say impermeable to liquid but permeable to gas such as air.
- This hydrophobic membrane 210 can be made of a material of the PTFE (Polytetrafluoroethylene) type.
- Two transverse walls of the support are made of a transparent material, thus making it possible to carry out an optical reading through the volume of the second chamber.
- transparent is understood to mean that the material used is at least partially transparent to visible light, so as to allow at least 80% of this light to pass. It should therefore be understood that it will be transparent enough to see the interior of the chamber.
- the lower wall may be made of glass and the upper wall may be formed of a removable adhesive bonded to close said second chamber from the upper side.
- the device also comprises a first transfer channel 22 formed in said support.
- This first transfer channel 22 is intended to connect the first chamber 10, more precisely its lower space 100, to the second chamber 20.
- the first transfer channel 22 has a first end opening directly into the second channel 12, thus forming a bypass node on this second channel 12. It has a second end opening directly into the second chamber.
- routing means may consist of a hollow removable cone 120 in the form of a funnel. When it is inserted by its tip into the second channel 12, it allows communication between the exterior and the first chamber and its wall closes the entrance to the first transfer channel 22, made at the branch node. When removed, the first end of the second channel 12 may be sealed, for example by means of an adhesive 121 applied to a surface of the support and the connection between the first transfer channel 22 and the second channel 12 is then open, allowing a fluid to circulate between the first chamber 10 and the second chamber 20.
- the device can be produced according to the architecture shown in figure 3 .
- the invention relates more particularly to the second chamber 20, called the amplification chamber.
- This amplification chamber has an architecture suitable for implementing the detection step described above.
- the amplification chamber in fact has an internal volume shaped in a suitable manner, either to ensure reliable control of the amplification reaction, or to identify several targets simultaneously. In the latter case, the chamber may be shaped to allow identification of several targets simultaneously.
- multiplex tests are for example used to detect groups of pathogenic organisms corresponding to similar clinical symptoms or to detect a bacterium but also its potential genes for resistance to antibiotics.
- the principle is to create at least one Ax alcove (x ranging from 1 to N, N corresponding to the number of alcoves and being greater than or equal to 1) in the amplification chamber, to house an internal reaction control compound.
- an internal reaction control compound for example a selected DNA sequence or amplification primers targeting a predefined DNA
- PCR amplification technology used
- LAMP RPA LAMP RPA
- This Ax alcove is advantageously created outside the section of the chamber dedicated to optical reading.
- the section of the chamber dedicated to optical reading corresponds to an optical reading zone Z.
- the optical reading zone Z is the only zone of the chamber visible to a C sensor.
- the chamber may have zones located outside this optical reading zone Z, and therefore outside the reading field of the sensor C.
- the internal control compound can be placed in the Ax alcove at a known concentration and then dried directly in the chamber. It thus remains permanently in the device and is ready for use.
- the advantage of depositing the compound not directly in the optical reading zone Z but outside it allows, in addition to optimizing the gas exchange space, to differentiate the control amplification from the amplification. target.
- the control amplification will indeed be both temporally and spatially shifted.
- the architecture of the device in several layers makes it possible to produce the amplification chamber with layers of different designs.
- the lower layer may in fact include one or more alcoves and the upper layers of the chamber define the total optical reading cross section of the chamber.
- the alcove A1 can be located outside the optical reading zone Z of sensor C.
- the amplification chamber is produced by superimposing the two strata S1, S2.
- the inlet channel in the chamber produced in the lower stratum S1 and corresponding to the first transfer channel 22.
- the figures 5A to 5C show different architectures of the lower stratum of the amplification chamber.
- the optical reading zone Z is shown in gray.
- the lower layer S1 has a protrusion forming the alcove A1 going beyond the section of the optical reading zone Z of the chamber in the transverse plane, opposite the point of entry of liquid into the chamber ( corresponding to the design of figures 4A and 4B ).
- This offset zone makes it possible to shift the amplification reaction temporally and spatially.
- the figure 5C shows a lower state, defining five distinct zones, four alcoves A1-A4 each made in the form of a cavity and a main zone comprising a protrusion presenting a fifth alcove A5.
- the upper layer of the chamber which is located just above defines the optical reading zone.
- the optical reading zone Z has a design covering the four alcoves A1 -A4 so that its volume is in fluid communication with them.
- the fifth alcove can be outside the optical reading zone Z, as in the design of the figure 5A .
- each primer can be placed in a separate alcove of the chamber, in a dry form.
- an acid buffer approximately pH 6
- sugars eg trehalose
- the chamber 20 has rounded angles and contours, making it possible to optimize the propagation of the liquid in the chamber and to avoid the formation of bubbles.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Dispersion Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Clinical Laboratory Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1908033A FR3098827A1 (fr) | 2019-07-17 | 2019-07-17 | Dispositif micro-fluidique incluant de réaction d'amplification |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3766581A1 true EP3766581A1 (de) | 2021-01-20 |
EP3766581B1 EP3766581B1 (de) | 2021-12-22 |
Family
ID=68072799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20184842.1A Active EP3766581B1 (de) | 2019-07-17 | 2020-07-09 | Mikrofluidisches system mit verstärkungsreaktionskammer |
Country Status (4)
Country | Link |
---|---|
US (1) | US11505823B2 (de) |
EP (1) | EP3766581B1 (de) |
JP (1) | JP2021035353A (de) |
FR (1) | FR3098827A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022049382A (ja) * | 2020-09-16 | 2022-03-29 | 株式会社エンプラス | 流体取扱装置および流体取扱装置の製造方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0586112A2 (de) | 1992-08-14 | 1994-03-09 | Pharma Gen, S.A. | Kontrolle der Detektion von Mikroorganismen mittels PCR |
US6312930B1 (en) | 1996-09-16 | 2001-11-06 | E. I. Du Pont De Nemours And Company | Method for detecting bacteria using PCR |
JP2009098039A (ja) * | 2007-10-18 | 2009-05-07 | Panasonic Corp | 分析容器と分析装置 |
US20100009431A1 (en) * | 2008-07-10 | 2010-01-14 | Samsung Electronics Co., Ltd. | Cartridge containing reagent, microfluidic device including the cartridge, method of manufacturing the microfluidic device, and biochemical analysis method using the microfluidic device |
US20170113221A1 (en) * | 2014-06-11 | 2017-04-27 | Micronics, Inc. | Microfluidic cartridges and apparatus with integrated assay controls for analysis of nucleic acids |
EP3173469A1 (de) * | 2014-07-23 | 2017-05-31 | Nanobiosys Inc. | Multiplex-pcr-chip und multiplex-pcr-vorrichtung damit |
EP3222989A1 (de) * | 2016-03-21 | 2017-09-27 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Analysevorrichtung für eine biologische probe |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3098826A1 (fr) * | 2019-07-17 | 2021-01-22 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Dispositif micro-fluidique de préparation et d'analyse d'un échantillon biologique |
-
2019
- 2019-07-17 FR FR1908033A patent/FR3098827A1/fr not_active Withdrawn
-
2020
- 2020-07-09 EP EP20184842.1A patent/EP3766581B1/de active Active
- 2020-07-16 US US16/930,765 patent/US11505823B2/en active Active
- 2020-07-16 JP JP2020122244A patent/JP2021035353A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0586112A2 (de) | 1992-08-14 | 1994-03-09 | Pharma Gen, S.A. | Kontrolle der Detektion von Mikroorganismen mittels PCR |
US6312930B1 (en) | 1996-09-16 | 2001-11-06 | E. I. Du Pont De Nemours And Company | Method for detecting bacteria using PCR |
JP2009098039A (ja) * | 2007-10-18 | 2009-05-07 | Panasonic Corp | 分析容器と分析装置 |
US20100009431A1 (en) * | 2008-07-10 | 2010-01-14 | Samsung Electronics Co., Ltd. | Cartridge containing reagent, microfluidic device including the cartridge, method of manufacturing the microfluidic device, and biochemical analysis method using the microfluidic device |
US20170113221A1 (en) * | 2014-06-11 | 2017-04-27 | Micronics, Inc. | Microfluidic cartridges and apparatus with integrated assay controls for analysis of nucleic acids |
EP3173469A1 (de) * | 2014-07-23 | 2017-05-31 | Nanobiosys Inc. | Multiplex-pcr-chip und multiplex-pcr-vorrichtung damit |
EP3222989A1 (de) * | 2016-03-21 | 2017-09-27 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Analysevorrichtung für eine biologische probe |
Also Published As
Publication number | Publication date |
---|---|
FR3098827A1 (fr) | 2021-01-22 |
US11505823B2 (en) | 2022-11-22 |
JP2021035353A (ja) | 2021-03-04 |
EP3766581B1 (de) | 2021-12-22 |
US20210017573A1 (en) | 2021-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3766580B1 (de) | Mikrofluidvorrichtung zur vorbereitung und analyse einer biologischen probe | |
EP3222989B1 (de) | Analysevorrichtung für eine biologische probe | |
EP2152850B1 (de) | Vorrichtung zur lysis von mikroorganismen aus einer umwelt- oder krankenhausprobe, probe und die entnahme von nukleinsäuren aus den besagten mikroorganismen zur analyse | |
FR2967362A1 (fr) | Cartouche microfluidique pour diagnostic moleculaire | |
FR2950358A1 (fr) | Dispositif d'amplification d'acides nucleiques simplifie et son procede de mise en oeuvrei | |
FR3086757A1 (fr) | Procede de preparation d'un echantillon biologique | |
EP3609994B1 (de) | Mikrobiologische testvorrichtung, verfahren zur bereitstellung und verwendung einer solchen vorrichtung | |
WO2016075410A1 (fr) | Procédé et dispositif de tri sélectif, spécifique et simultané de cellules rares cibles dans un échantillon biologique | |
EP3766581B1 (de) | Mikrofluidisches system mit verstärkungsreaktionskammer | |
EP2872867B1 (de) | Automatisiertes system zur lyse von mikroorganismen in einer probe sowie zur extraktion und reinigung der nukleinsäuren aus den besagten mikroorganismen zur analyse | |
EP3967402A1 (de) | Verfahren zur vorbereitung einer biologischen probe und zum nachweis von biologischen spezies in der biologischen probe | |
FR3109585A1 (fr) | Plaquette de test et système de test biologique automatisé | |
EP3880365B1 (de) | Automatisiertes system zur vorbereitung, detektion und analyse einer flüssigkeitsprobe | |
EP3654011B1 (de) | Präparationsverfahren einer zu analysierenden probe, die aus einer lebensmittelmatrix erhalten wurde | |
FR3030049A1 (fr) | Systeme d'analyse et de culture cellulaire, procede d'analyse et de culture cellulaire associe et methode de fabrication de la puce associee | |
WO2023011950A1 (fr) | Support de test biologique ameliore | |
EP2635891A1 (de) | Verfahren und vorrichtungen zur analyse von bestandteilen enthalten in der luft |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200709 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: B01L 3/00 20060101AFI20210719BHEP Ipc: B01L 7/00 20060101ALN20210719BHEP Ipc: C12Q 1/6844 20180101ALN20210719BHEP |
|
INTG | Intention to grant announced |
Effective date: 20210804 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602020001367 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1456722 Country of ref document: AT Kind code of ref document: T Effective date: 20220115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220322 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20211222 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1456722 Country of ref document: AT Kind code of ref document: T Effective date: 20211222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220322 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220422 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602020001367 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220422 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 |
|
26N | No opposition filed |
Effective date: 20220923 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20220731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220709 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220709 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230724 Year of fee payment: 4 Ref country code: DE Payment date: 20230720 Year of fee payment: 4 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211222 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20200709 |